Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Enliven Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Enliven Therapeutics, Inc.

ELVN IMRA

Enliven Therapeutics, Inc.

About Enliven Therapeutics, Inc.

Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting validated cancer drivers. Its focus includes precision oncology treatments for conditions like chronic myeloid leukemia and HER2-driven cancers. The company leverages differentiated chemistry and validated biology to create targeted, tolerable therapies aimed at overcoming resistance and improving patient outcomes across global markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Enliven Therapeutics, Inc.

1
1
Enliven Therapeutics, Inc. Enliven Therapeutics Reports $23.6 Million Net Loss in Q1 2026, Focuses on BCR-ABL Program

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Enliven Therapeutics, Inc. Enliven Therapeutics Reports $103.7 Million Net Loss for 2025, Focuses on ELVN-001 Development

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Enliven Therapeutics, Inc. Enliven Therapeutics Reports $20.1 Million Net Loss in Q3 2025, Cash Reserves Increase to $477.6 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Enliven Therapeutics, Inc. Enliven Therapeutics Reports $25.3 Million Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Enliven Therapeutics, Inc. Enliven Therapeutics Reports $28.5 Million Net Loss in Q1 2025 Amid Increased R&D Costs

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Enliven Therapeutics, Inc. Enliven Therapeutics Reports $89M Net Loss for 2024, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Enliven Therapeutics, Inc. Enliven Therapeutics Reports Increased Assets, Continued Operating Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments